The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%

Karbownik A, Szałek E, Urjasz H, Głęboka A, Mierzwa E, Grześkowiak E. The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemporary Oncology/Współczesna Onkologia. 2012;16(5):435-439. doi:10.5114/wo.2012.31775.

APA

Karbownik, A., Szałek, E., Urjasz, H., Głęboka, A., Mierzwa, E.,  & Grześkowiak, E. (2012). The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemporary Oncology/Współczesna Onkologia, 16(5), 435-439. https://doi.org/10.5114/wo.2012.31775

Chicago

Karbownik, Agnieszka, Edyta Szałek, Hanna Urjasz, Aleksandra Głęboka, Emilia Mierzwa,  and Edmund Grześkowiak. 2012. "The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%". Contemporary Oncology/Współczesna Onkologia 16 (5): 435-439. doi:10.5114/wo.2012.31775.

Harvard

Karbownik, A., Szałek, E., Urjasz, H., Głęboka, A., Mierzwa, E.,  and Grześkowiak, E. (2012). The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemporary Oncology/Współczesna Onkologia, 16(5), pp.435-439. https://doi.org/10.5114/wo.2012.31775

MLA

Karbownik, Agnieszka et al. "The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%." Contemporary Oncology/Współczesna Onkologia, vol. 16, no. 5, 2012, pp. 435-439. doi:10.5114/wo.2012.31775.

Vancouver

Karbownik A, Szałek E, Urjasz H, Głęboka A, Mierzwa E, Grześkowiak E. The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemporary Oncology/Współczesna Onkologia. 2012;16(5):435-439. doi:10.5114/wo.2012.31775.

Aim of the study: The subject of study was the stability of cisplatin in concentrate in glass vials and diluted in polyethylene (PE) bags stored at 15–25°C for up to 30 days.

Material and methods: Original vials of cisplatin injection (1 mg/ml, Teva) were stored at room temperature and subjected to re-piercing after 1, 2, 3, 7, 14, 21, 28 and 30 days following the initial piercing. Cisplatin infusions at nominal concentrations of 0.1 mg/ml were prepared in 0.9% sodium chloride (1000 ml) in PE bags. Chemical stability was measured by means of a stability-indicating high-performance liquid chromatography (HPLC) assay. Physical stability was assessed by visual inspection in normal light.

Results: The concentration of cisplatin at each sampling time in the analysed solutions remained within 92.0–100.7% of initial concentration, regardless of the container. No changes in colour or turbidity were observed in any of the vials or prepared solutions.

Conclusions: Cisplatin, both undiluted in glass containers and diluted with NaCl 0.9% in PE bags, remains stable (< 10% degradation) for at least 30 days at room temperature when protected from light.

keywords:

cisplatin, stability, concentrate, infusion

references:

Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 2003; 1: 47-61.

Piulats JM, Jiménez L, García del Muro X, Villanueva A, Vin~als F, Germa`-Lluch JR. Molecular mechanism behind the resistance of cisplatin in germ cell tumours. Clin Transl Oncol 2009; 11: 780-6.

Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010; 2: 2490-518.

Baskerville-Abraham IM, Boysen G, Troutman JM, et al. Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts. Chem Res Toxicol 2009; 22: 905-12.

Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7: 3-18.

Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-63.

Sewell G. Physical and chemical stability of cisplatin infusions in PVC containers. EJOP 2010; 4: 11-3.

Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque M. Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material. Pharm World Sci 1993; 15: 34-6.

Allwood M, Stanley A, Wright P. The cytotoxics handbook. Radcliffe Publishing, Abingdon 2002; 286-9, 414-6, 426-7.

Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE. Characterization of cisplatin degradation as affected by pH and light. Am J Hosp Pharm 1991; 48: 1500-6.

Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW. Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. Cancer Chemother Pharmacol 1992; 29: 252-5.

Mittner A, Vincze Z, Jemnitz K. Stability of cisplatin containing infusion. Pharmazie 1998; 53: 490-2.

Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque M. Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material. Pharm World Sci 1993; 15: 34-6.

Rochard E, Barthes D, Courtois P. Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs. J Clin Pharm Ther 1992; 17: 315-8.

Lecompte D, Bousselet M, Gayrard D, Poitou P. Stability study of reconstituted and diluted solutions of calcium folinate. Pharm Ind 1991; 53: 90-4.

Astier A, Pinguet F, Vigneron J. The practical stability of anticancer drugs: SFPO and ESOP recommendations. EJOP 2010; 4: 4-6.

Bardin C, Astier A, Vulto A, et al. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr 2011; 69: 221-31